However, before the employment of CAR-T cell therapy, several changes in the tumor microenvironment should be considered, as in a clinical trial of CEA CAR-T cells that increased the resistance of CEA+ rectal cancer tumor immunity [60].Two current phase I trials are recruiting subjects. The gene discussed is CEACAM5; the disease is neoplasm.